Summit Therapeutics Inc. (SMMT) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Summit Therapeutics Inc.

    NASDAQ: SMMT · Real-Time Price · USD
    23.46
    1.17 (5.25%)
    At close: Oct 08, 2025, 12:32 PM

    Summit Therapeutics Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 n/a n/a 704.29K 1.81M
    Cost of Revenue
    		 15.01M 2.05M 2.51M n/a
    Gross Profit
    		 -15.01M -2.05M -1.81M 1.81M
    Operating Income
    		 313K -89.74M -59.63M -86.19M
    Interest Income
    		 13.47M 10.4M 1.51M 178.95K
    Pretax Income
    		 -221.31M -615.87M -78.78M -88.6M
    Net Income
    		 -221.31M -614.93M -78.78M -88.6M
    Selling & General & Admin
    		 60.53M 30.27M 26.7M 23.61M
    Research & Development
    		 150.78M 59.47M 52M 85.35M
    Other Expenses
    		 n/a n/a -5.95M -20.97M
    Operating Expenses
    		 211.3M 87.69M 64.28M 88M
    Interest Expense
    		 8.69M 16.46M 4.4M 281K
    Selling & Marketing Expenses
    		 n/a -2.05M n/a n/a
    Cost & Expenses
    		 211.3M 89.74M 72.79M 65.07M
    Income Tax Expense
    		 -313K -946K -4.4M n/a
    Shares Outstanding (Basic)
    		 718.54M 619.65M 193.34M 92.24M
    Shares Outstanding (Diluted)
    		 718.54M 619.65M 193.34M 92.24M
    EPS (Basic)
    		 -0.31 -0.99 -0.41 -0.96
    EPS (Diluted)
    		 -0.31 -0.99 -0.38 -0.96
    EBITDA
    		 -212.85M 1M -73.12M -85.91M
    EBIT
    		 -230M -69.61M -74.38M -88.36M
    Depreciation & Amortization
    		 17.15M 155.32K 1.26M 2.46M

    Add to Watchlist